AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
18 August A weak spot in the spike protein of SARS-CoV-2 is described by researchers, which an antibody fragment called VH Ab6 can attach to, potentially neutralising all major variants of the virus. On 11 August, researchers report a single antibody, SP1-77, that could potentially neutralize all known variants of the virus via a novel mechanism, not by not preventing the virus from binding to ACE2 receptors but by blocking it from fusing with host cells' membranes. Multiple gene editing of soybean is shown to improve photosynthesis and boost yields by 20%. A researcher reports that the social media app TikTok adds a keylogger to its, on iOS essentially unavoidable, in-app browser in iOS, which allows its Chinese company to gather, for example, passwords, credit card details, and everything else that is typed into websites opened from taps on any external links within the app. Shortly after the report, the company claims such capabilities are only used for debugging-types of purposes. To date, it has largely not been investigated which and to which extent (other) apps have capacities for such or similar data-collection. A university reports the development of an invisible coating for fireproof wood. 20 August – A GBD systematic analysis reports the (non)progress on cancer and its causes during the 2010-19 decade, with ~44% of all cancer deaths in 2019 – or ~4.5 M deaths or ~105 million lost DALYs – due to known clearly preventable risk factors (contributions), led by smoking, alcohol use and high BMI.
With time, the mechanical complexity of TSP was simplified, and this interface became popular as the first ideal LC–MS interface for pharmaceutical applications comprising the analysis of drugs, metabolites, conjugates, nucleosides, peptides, natural products, and pesticides. The introduction of TSP marked a significant improvement for LC–MS systems and was the most widely applied interface until the beginning of the 1990s, when it began to be replaced by interfaces involving atmospheric pressure ionization (API).
Communication between networks of the Moroccan mafia was mostly exercised by the use of Blackberry smartphone messaging equipped with PGP technology. On 19 April 2016, the Canadian authorities intervened a hosting company with the aim of decrypting the Dutch telecommunication servers of Ennetcom. The servers contained millions of messages that were sent through Ennetcom. The cybercrime investigators of the Netherlands Forensic Institute finally managed to decrypt the messages in Canada. When the messages were deciphered, the investigators found out that the messages were all written in Tarifit, a language that was unknown to them. The names of the criminals were also replaced by nicknames. Between 2016 and 2018, the Dutch police forces investigated the nicknames to identify commanders as well as contract killers. Following the dismantling of the Ennetcom network, several criminal organisations have converted to the use of other encrypted communication services. Some criminals, including Saïd Razzouki, have been avoiding to communicate through electronic devices. Because of this, Razzouki could operate unknowingly for over 8 years before being arrested in Medellín by the DEA and FBI. Commanders or crime bosses are rarely found in Europe. They often stay hidden under the radar in places like Morocco, Latin-America, Arab states of the Persian Gulf, and Thailand.
An aqueous environment is essential at all stages of array manufacture and operation to prevent protein denaturation. Therefore, sample buffers contain a high percent of glycerol (to lower the freezing point), and the humidity of the manufacturing environment is carefully regulated. Microwells have the dual advantage of providing an aqueous environment while preventing cross-contamination between samples. In the most common type of protein array, robots place large numbers of proteins or their ligands onto a coated solid support in a pre-defined pattern. This is known as robotic contact printing or robotic spotting. Another fabrication method is ink-jetting, a drop-on-demand, non-contact method of dispersing the protein polymers onto the solid surface in the desired pattern. Piezoelectric spotting is a similar method to ink-jet printing. The printhead moves across the array, and at each spot uses electric stimulation to deliver the protein molecules onto the surface via tiny jets. This is also a non-contact process. Photolithography is a fourth method of arraying the proteins onto the surface. Light is used in association with photomasks, opaque plates with holes or transparencies that allow light to shine through in a defined pattern. A series of chemical treatments then enables deposition of the protein in the desired pattern upon the material underneath the photomask.
Fibronectin is a high molecular weight (approximately 500–600 kDa) glycoprotein of the extracellular matrix that binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans (e.g. syndecans). Fibronectin exists as a protein dimer, consisting of two nearly identical monomers linked by a pair of disulfide bonds. The fibronectin protein is produced from a single gene, but alternative splicing of its pre-mRNA leads to the creation of several isoforms. Two types of fibronectin are present in vertebrates:
Sources: en.wikipedia.org
== Applications == When processed industrially, 1,000 kg of bones yield 300 kg of ossein, which can be rapidly degraded and partially denatured by the prolonged action of slightly acidic boiling water, yielding gelatin. The product is specifically known as ossein gelatin in contrast to skin gelatin, which is generated from animal hides. Depending on the method of extraction, there are various types of ossein gelatin (acid ossein gelatin, limed ossein gelatin, etc.). Another prominent use of ossein is the production of bone glue, whose yield is 16-20% of the mass of dry bone. Bones that are unsuitable for ossein production can be carbonized to generate bone char, used to filter water among other uses.
== Research == Given the difficulty in treating scleroderma, treatments with a smaller evidence base are often tried to control the disease. These include antithymocyte globulin and mycophenolate mofetil; some reports have shown improvements in the skin symptoms, as well as delaying the progress of systemic disease, but neither has been subjected to large clinical trials. Autologous hematopoietic stem cell transplantation (HSCT) is based on the assumption that autoimmune diseases such as systemic sclerosis occur when the white blood cells of the immune system attack the body. In this treatment, stem cells from the patient's blood are extracted and stored to preserve them. The patient's white blood cells are destroyed with cyclophosphamide and rabbit antibodies against the white blood cells. Then, the stored blood is returned to the patient's bloodstream to reconstitute a healthy blood and immune system that will not attack the body. The results of a phase-III trial, the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, with 156 patients, were published in 2014. HSCT itself has a high treatment mortality, so in the first year, the survival of patients in the treatment group was lower than the placebo group, but at the end of 10 years, the survival in the treatment group was significantly higher. The authors concluded that HSCT could be effective, if limited to patients who were healthy enough to survive HSCT itself. Therefore, HSCT should be given early in the progression of the disease, before it does damage.
=== Differential diagnosis === Given the variety and nonspecific nature of symptoms that can be associated with autoimmune diseases, differential diagnosis—determining which of several diseases with similar symptoms is causing a patient's illness—is an important part of the diagnostic process. This often involves ruling out other potential causes of symptoms, such as infections, malignancies, or genetic disorders.
Many fast food chains stopped use of the product after the controversy arose, or stated that they had not used the product before. In April 2012, the Concord Monitor reported increased business in some small neighborhood markets where the product's use was less likely, due to consumer concerns about the additive. In March 2012, 70% of ground beef in the U.S. contained lean finely textured beef, and a year later, in March 2013, the amount was estimated by meat industry officials to be at approximately 5%. This significant reduction is due in part to the extensive media coverage that began in March 2012 about the additive. Kroger Co. and Supervalu Inc. stopped using the additive. On March 25, 2012, BPI announced it would suspend operations at three of its four plants, being in "crisis planning". The three plants produced a total of about 900,000 pounds of the product per day. BPI said it lost contracts with 72 customers, many over the course of one weekend, and production decreased from 5 million pounds of LFTB per week to below one million pounds a week at the nadir (lowest point of production). Effective May 25, 2012, BPI closed three of its four plants, including one in Garden City, Kansas, lost more than $400 million in sales, and laid off 700 workers. Production decreased to less than 2 million pounds in 2013. Cargill also significantly cut production of finely textured beef and in April 2012 "warned [that] the public's resistance to the filler could lead to higher hamburger prices this barbecue season".
=== Pharmacokinetics === Oral bioavailability of diphenhydramine is in the range of 40% to 60%, and peak plasma concentration occurs about 2 to 3 hours after administration. Diphenhydramine, available in various salt forms, such as citrate, hydrochloride, and salicylate, exhibits distinct molecular weights and pharmacokinetic properties. Specifically, diphenhydramine hydrochloride and diphenhydramine citrate possess molecular weights of 291.8 g/mol and 447.5 g/mol, respectively. These variations in molecular weight influence the dissolution rates and absorption characteristics of each salt form. The primary route of metabolism is two successive demethylations of the tertiary amine. The resulting primary amine is further oxidized to the carboxylic acid. Diphenhydramine is metabolized by the cytochrome P450 enzymes CYP2D6, CYP1A2, CYP2C9, and CYP2C19. The elimination half-life of diphenhydramine has not been fully elucidated, but appears to range between 2.4 and 9.3 hours in healthy adults. A 1985 review of antihistamine pharmacokinetics found that the elimination half-life of diphenhydramine ranged between 3.4 and 9.3 hours across five studies, with a median elimination half-life of 4.3 hours. A subsequent 1990 study found that the elimination half-life of diphenhydramine was 5.4 hours in children, 9.2 hours in young adults, and 13.5 hours in the elderly. A 1998 study found a half-life of 4.1 ± 0.3 hours in young men, 7.4 ± 3.0 hours in elderly men, 4.4 ± 0.3 hours in young women, and 4.9 ± 0.6 hours in elderly women.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.